A Phase IV, Randomised Study to Evaluate the Immune Responses of UK Adolescent Girls Receiving CervarixTM or GardasilTM Human Papillomavirus Vaccines
This study looks at possible cross reactivity between different HPV serotypes and both
peripheral antibodies and mucosally-secreted antibodies.
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention
Measurable antibody mediated neutralisation of HPV serotype 6, 11, 16, 18 and genetically related serotypes, especially 45
18 months from enrollment
United Kingdom: Medicines and Healthcare Products Regulatory Agency